The Growing Pseudomonas Threat in Indian ICUs

Colistin resistance in Pseudomonas aeruginosa is accelerating at an alarming rate, threatening the very foundation of critical care in Indian hospitals. A landmark study from Oxford University reveals that a single gene mutation allows this hospital superbug to evade the last-resort antibiotic at speeds 1,000 times faster than normal background mutation rates. For patients in intensive care units across AIIMS Delhi, PGIMER Chandigarh and other tertiary care centres, this development signals a deepening crisis in antimicrobial resistance that demands immediate policy recalibration.

The Growing Pseudomonas Threat in Indian ICUs

Pseudomonas aeruginosa stands as one of the most formidable gram-negative, non-fermenting bacilli responsible for hospital-acquired infections worldwide. In India, this opportunistic pathogen frequently triggers ventilator-associated pneumonias, bloodstream infections, surgical wound complications, urinary tract infections and severe sepsis among immunocompromised patients. Data from the Indian Council of Medical Research’s Antimicrobial Resistance Surveillance Network (AMRSN) consistently rank Pseudomonas among the top six pathogenic groups monitored across 30 nodal and regional centres.

According to ICMR reports, Pseudomonas aeruginosa accounts for nearly 20 per cent of all gram-negative isolates in Indian intensive care settings. The bacterium thrives in moist hospital environments, colonising ventilators, sinks, catheters and dialysis equipment. Patients undergoing prolonged mechanical ventilation or those with burns, trauma or cancer face the highest risk. A 2026 Frontiers in Medicine study on the current AMR status in India documented that multidrug-resistant Pseudomonas strains have become endemic in most tertiary care hospitals from Delhi to Chennai and Mumbai to Guwahati.

The clinical impact is devastating. Indian studies reveal that approximately 40 per cent of ICU patients infected with such superbugs die within 14 days despite aggressive treatment. This mortality figure, drawn from multiple AIIMS-coordinated cohorts, far exceeds global averages and places enormous pressure on both public and private healthcare infrastructure. With over 1 million people dying annually worldwide from antibiotic-resistant infections, India shoulders a disproportionate burden given its dense population and high antibiotic consumption rates.

Understanding Colistin: The Last-Resort Antibiotic

Colistin, a member of the polymyxin class, has served as the final defensive line against gram-negative superbugs when all other antibiotics fail. Discovered in the 1940s but largely abandoned due to toxicity concerns, the drug experienced a renaissance in the early 2000s as carbapenem resistance surged globally. In Indian hospitals, colistin is routinely deployed against extensively drug-resistant Pseudomonas, Acinetobacter and Klebsiella isolates when carbapenems, tigecycline and aminoglycosides prove ineffective.

The antibiotic works by disrupting the outer membrane of gram-negative bacteria. Its positively charged molecules bind to negatively charged lipopolysaccharides, causing leakage of cellular contents and eventual bacterial death. However, colistin carries significant dose-dependent nephrotoxicity and neurotoxicity, limiting its clinical utility. Indian clinicians at AIIMS Delhi and other centres often face the difficult choice between risking kidney damage in already critically ill patients or allowing unchecked infection progression.

The National Centre for Disease Control (NCDC) has repeatedly highlighted in its annual reports that colistin consumption in India has risen sharply since 2015. This increased reliance coincides with the spread of both chromosomal mutations and plasmid-mediated resistance mechanisms. While chromosomal changes such as those in the pmrB gene dominate in Pseudomonas, the emergence of mobile colistin resistance genes (MCR-1 through MCR-10) has complicated the picture across multiple bacterial species.

The pmrB Mutation Mechanism Driving Rapid Resistance

At the heart of the new Oxford findings lies the pmrB gene, which encodes a sensor kinase in the two-component regulatory system governing lipid A modification. When mutated, pmrB triggers the addition of positively charged groups to the bacterial outer membrane, effectively repelling colistin molecules before they can bind. What makes this mechanism particularly dangerous is its hypermutability.

Professor Craig MacLean and his colleagues at the Department of Biology, Oxford University, discovered that pmrB mutations occur at a rate 1,000 times higher than normal background mutation rates. This elevated mutation frequency allows Pseudomonas aeruginosa populations to generate resistant variants within days rather than weeks or months. The study, published in Cell Reports in July 2026, provides the most comprehensive experimental validation of this phenomenon to date.

Researchers cultured more than 900 independent populations of Pseudomonas aeruginosa and subjected them to controlled colistin exposure. Whole-genome sequencing revealed that pmrB alterations consistently emerged as the dominant resistance pathway. These mutations conferred high-level resistance without imposing severe fitness costs on the bacteria, meaning resistant strains could persist even in the absence of antibiotic pressure. Such evolutionary adaptability poses unique challenges for Indian hospitals where infection control standards vary widely between facilities.

Key Findings from the Oxford University Study

The Oxford team’s experimental design was both rigorous and clinically relevant. By evolving 900-plus bacterial populations under colistin selection, Professor Craig MacLean’s group mapped the precise genetic routes to resistance with unprecedented resolution. Their data demonstrate that pmrB mutations arise rapidly and repeatedly, often within the first 48 to 72 hours of exposure.

Beyond documenting the 1,000-fold mutation rate increase, the study uncovered a surprising reversibility. When colistin pressure was removed, resistant populations frequently lost their protective mutations and reverted to susceptibility. This finding carries profound implications for antibiotic stewardship programmes. The research also distinguished between stable chromosomal resistance and the more mobile plasmid-mediated MCR genes (MCR-1 to MCR-10), noting that pmrB-driven resistance predominates in Pseudomonas clinical isolates.

These results align with earlier genomic surveillance from India. A February 2026 Nature study on the genomic landscape of AMR in India, which analysed thousands of isolates from across the country, similarly emphasised the importance of developing molecular diagnostics targeting pmrB and related regulatory genes. The Oxford data now provide mechanistic clarity that Indian researchers can leverage to refine local testing protocols at ICMR reference laboratories.

The Indian AMR Landscape: Data from ICMR, NCDC and AIIMS

India’s response to antimicrobial resistance rests on a multi-institutional framework coordinated by the Indian Council of Medical Research and the National Centre for Disease Control. The AMRSN, launched in 2014, now encompasses more than 30 surveillance sites collecting standardised data on six priority pathogens, including Pseudomonas aeruginosa. Recent AMRSN reports indicate colistin resistance rates in Pseudomonas ranging from 8 to 15 per cent in major metropolitan ICUs, with pockets exceeding 25 per cent in certain northern and eastern centres.

AIIMS Delhi has emerged as a key node in this network, contributing longitudinal data that reveal a steady upward trend in colistin non-susceptibility since 2018. The National Academy of Medical Sciences (NAMS) task force report published in April 2025 warned that without urgent intervention, pan-resistant gram-negative infections could become commonplace in Indian tertiary care hospitals within the next decade. The report specifically flagged Pseudomonas and Acinetobacter as priority threats requiring novel therapeutic approaches.

Urban sewage surveillance conducted by NCDC further illustrates the environmental dimension of this crisis. Antibiotic-resistant bacteria and resistance genes are ubiquitous in water bodies receiving hospital and pharmaceutical effluents, particularly in cities like Hyderabad, Bengaluru and Ahmedabad. The Ministry of Health and Family Welfare’s National Action Plan on AMR, updated in 2022, seeks to address this through improved infection prevention, reduced antibiotic misuse in healthcare and agriculture, and strengthened surveillance. However, implementation gaps persist at district and rural levels.

What This Means for India

The Oxford study’s revelation of rapid pmrB-mediated colistin resistance carries direct and urgent consequences for Indian patients, doctors and healthcare economics. With 40 per cent ICU mortality among superbug-infected patients already documented in domestic cohorts, any further erosion of colistin efficacy could push case fatality rates even higher. This would translate into thousands of additional preventable deaths annually across government and private hospitals from Kerala to Kashmir.

For clinicians at AIIMS and other teaching hospitals, the findings necessitate immediate review of empirical colistin prescribing protocols. The paradoxical reversal of resistance when colistin use is temporarily suspended offers a practical tool for stewardship teams. Hospitals could implement “antibiotic holidays” for specific high-dependency units, cycling away from polymyxins for defined periods to restore susceptibility. Such strategies would require robust real-time surveillance data from the AMRSN network and close coordination between microbiologists and intensivists.

Taxpayers and health insurance systems would bear the downstream costs of prolonged ICU stays, dialysis for colistin-induced kidney injury, and newer, more expensive therapies. The Chennai Declaration of 2012, which galvanised national attention on antibiotic stewardship, must now be revisited with fresh urgency. Integrating pmrB molecular testing into routine diagnostics, as recommended by the 2026 Nature genomic study, could help clinicians reserve colistin for truly susceptible cases while fast-tracking alternative regimens.

The broader economic impact extends beyond healthcare. India’s position as a major pharmaceutical producer and exporter makes responsible antibiotic use both a domestic necessity and a global responsibility. Rising colistin resistance threatens medical tourism, compromises surgical outcomes and undermines progress toward universal health coverage under Ayushman Bharat.

The Paradoxical Reversal Finding and Antibiotic Stewardship

Perhaps the most encouraging aspect of the Oxford research is the demonstration that Pseudomonas aeruginosa can lose colistin resistance when selective pressure is removed. Professor Craig MacLean’s team observed that resistant mutants frequently accumulated compensatory mutations that restored membrane stability once colistin was withdrawn. In evolutionary terms, the fitness cost of maintaining resistance became disadvantageous in antibiotic-free environments.

This reversibility opens new avenues for cycling and stewardship strategies tailored to Indian conditions. The NCDC has already piloted antibiotic cycling protocols in selected ICUs with promising early results. When colistin usage was deliberately reduced for six months in one Delhi hospital network, susceptibility rates improved by nearly 12 percentage points. Scaling such interventions across the AMRSN network could preserve colistin’s effectiveness for future generations.

However, successful implementation demands stringent infection control. If resistant strains continue to spread through contaminated hands, equipment or hospital sewage, the benefits of cycling will be short-lived. The Ministry of Health’s AMR action plan must therefore integrate environmental surveillance with clinical stewardship. Urban sewage data showing high levels of resistance genes underscore the need for wastewater treatment reforms in hospital clusters.

Forward-Looking Analysis: Policy Directions for Indian Healthcare

The convergence of Oxford’s mechanistic insights with India’s robust surveillance infrastructure creates a rare window for evidence-based policy reform. The NAMS task force has already called for accelerated development of molecular diagnostics targeting pmrB and MCR genes. Integrating these tests into the AMRSN workflow at AIIMS and regional labs would enable precision prescribing and reduce unnecessary colistin exposure.

Investment in novel therapeutics remains critical. While waiting for new antibiotics or phage therapies, Indian researchers should explore combination regimens, enhanced infection control bundles and microbiome-sparing approaches. The WHO’s global priority pathogen list places carbapenem-resistant Pseudomonas at the highest urgency level, making India’s domestic research output particularly consequential.

Long-term success will depend on addressing upstream drivers of resistance. Regulating over-the-counter antibiotic sales, curtailing unnecessary use in poultry and aquaculture, and improving sanitation infrastructure must complement hospital-focused interventions. The 2026 Frontiers study emphasises that nationally representative data from AMRSN provide the perfect platform for monitoring intervention effectiveness.

Professor Craig MacLean’s work reminds us that bacteria evolve faster than our regulatory systems. For Indian policymakers, the message is clear: colistin must be protected through intelligent, data-driven stewardship rather than reflexive last-resort deployment. The lives of thousands of ICU patients in tertiary care hospitals across the country depend on translating these Oxford findings into practical policy before resistance becomes irreversible.

Indian science has repeatedly demonstrated its capacity to generate world-class data on AMR. Now is the time to convert that knowledge into decisive action that safeguards both current patients and future generations. The Oxford study on pmrB hypermutability provides not just a warning but a roadmap for preserving one of medicine’s most critical tools.

— By Dr. Raj Patel, Staff Writer